Under a binding deal valued at EUR 48 million, Mankind Pharma will acquire a 70% ownership stake in ACTx — Armed Cell Therapeutics, a biotechnology firm headquartered in Belgium — with the transaction providing the Indian drugmaker with a path into next-generation CAR-T cancer treatment development. The deal fits within the company's broader strategy for expanding its worldwide footprint in next-generation therapies.
The acquisition will be executed through Mankind Pharma (Netherlands) B.V., a dedicated subsidiary, giving the company access to ACTx's research pipeline, which includes oncology drug-development programmes targeting non-Hodgkin lymphoma and small cell lung cancer. Under this arrangement, Mankind Pharma stands to deepen its position in advanced oncology research.
Pursuant to the terms of the agreement, Armed Cell Therapeutics would transfer a 70% ownership share to Mankind Pharma in exchange for a EUR 48 million commitment. The deal is structured to give Mankind Pharma a position in next-generation CAR-T research while broadening its reach into therapeutically demanding treatment categories.
Armed Cell Therapeutics B.V.'s pipeline is centred on non-Hodgkin lymphoma and small cell lung cancer through next-generation armed CAR-T approaches, among them methods for generating CAR-T cells directly within the body. Dedicated teams operating out of facilities in the United States and Europe carry out the company's research and development work.
Chimeric antigen receptor T-cell therapy, or CAR-T, is derived from a patient's own immune cells; extracted T cells are reconfigured to locate and attack tumour tissue. CAR-T therapies have produced considerable shifts in outcomes for patients with certain blood cancers, though obstacles — among them treatment resistance, the limited persistence of CAR-T cells, and disease recurrence — continue to present challenges in the field.
Armed Cell Therapeutics is developing a portfolio of next-generation CAR-T therapies designed to address longstanding hurdles in the field. The organisation modifies CAR-T cells to carry additional molecular components intended to bolster and prolong their tumour-fighting capacity. Work on limiting tumour immune evasion has led the company toward multi-antigen approaches, where therapies are designed to target several cancer antigens simultaneously rather than a single one.
Those programmes remain within the research and development pipeline, and any practical value they deliver will depend on how testing and clinical evaluation proceed. Two priority areas for Armed Cell Therapeutics' next-generation CAR-T programme have been identified through the company's internal research process.
Cancers falling under the non-Hodgkin lymphoma umbrella originate within the lymphatic system and span a wide range of distinct disease types. Tumour recurrence continues to present a challenge for patients even after CAR-T treatment, and work on extending the durability and effectiveness of CAR-T responses is central to ACTx's current programme development.
Among lung cancers, the small cell variant progresses rapidly and has historically shown resistance to most available therapies. This cancer type holds a dedicated place within ACTx's development portfolio, as part of a broader effort to extend CAR-T technology into disease areas beyond its established foothold in haematological conditions. These programmes remain within active research efforts and carry no regulatory approval for clinical or commercial use.
Mankind Pharma's Chief Operating Officer, Arjun Juneja, described the funding commitment as a foundational move toward assembling a worldwide portfolio of next-generation treatments. In his remarks, Juneja highlighted three areas: access to advanced scientific platforms, leadership with relevant experience, and pathways for developing next-generation CAR-T candidates.
Mankind Pharma holds a position across two segments of the Indian market — pharmaceutical formulations and consumer healthcare. Treatment categories within the portfolio range from anti-infectives and cardiovascular drugs through to gastrointestinal, antidiabetic, neuro/CNS, gynaecological, and respiratory medicines, covering both acute conditions and chronic disease management. Supporting that distribution reach are 32 production plants and seven dedicated R&D centres spread across India, where a workforce of more than 740 scientists carries out research activity.
Armed Cell Therapeutics' leadership team comprises three individuals whose backgrounds span drug development, cell therapy, and the broader biotechnology sector. Dr. Paul Stoffels serves as board chair, having previously held the chief executive role at Galapagos as well as the positions of vice chairman and chief scientific officer at Johnson & Johnson. Dr. John Mellors occupies the chief scientific officer post while holding a distinguished professorship in medicine at the University of Pittsburgh and carrying a background in senior executive work at Galapagos. Peter Verhaeghe's professional background spans corporate finance, life sciences law, and a prior chairmanship at argenx.
The company maintains operations across Belgium, where its headquarters are located, the Netherlands, Pittsburgh in the United States — home to its research and pre-clinical work — and multiple sites across Europe, Asia, and the United States devoted to early-development CAR-T programmes. The value the transaction ultimately generates will depend on where ACTx's research programmes lead, what clinical results emerge, and whether potential therapies are able to navigate the regulatory approvals process.
